62321-91-9 Usage
General Description
4-(Dimethylamino)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile is a chemical compound belonging to the organic category. It has a molecular formula of C9H9N3O. The substance is an aromatic heteropolycyclic compound and is a member of pyridines, characterized by a six-membered aromatic ring with two nitrogen atoms. Specific properties such as melting and boiling points, solubility, and toxicity depend on factors like temperature and pressure. It is generally used in scientific research and chemical industries for various purposes, often serving as a chemical intermediate in the preparation of other more complex compounds. However, handling must be done with caution because its exact hazard specifications and potential health impacts are not fully known.
Check Digit Verification of cas no
The CAS Registry Mumber 62321-91-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,3,2 and 1 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 62321-91:
(7*6)+(6*2)+(5*3)+(4*2)+(3*1)+(2*9)+(1*1)=99
99 % 10 = 9
So 62321-91-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H9N3O/c1-11(2)7-3-4-10-8(12)6(7)5-9/h3-4H,1-2H3,(H,10,12)
62321-91-9Relevant articles and documents
FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS
-
Page/Page column 45; 47-48, (2010/11/26)
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, part
mGluR1 antagonists as therapeutic agents
-
Page/Page column 65; 81, (2008/06/13)
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
